Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Validation of fermentation processes.

A S Lubiniecki1, A R Gardner, T M Smith

  • 1GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406, USA. Anthony_lubiniecki@sbphrd.com

Developments in Biologicals
|November 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation leads to greater clonality and reduced seed production in a temperate seagrass.

Annals of botany·2026
Same author

[Functional analysis of laparoscopic intracorporeal Xing's neobladder in long-term follow-up].

Zhonghua yi xue za zhi·2024
Same author

[Analysis on transmission chain of a cluster epidemic of COVID-19, Nanchang].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2020
Same author

Efficient production of a high-performance dispersion strengthened, multi-principal element alloy.

Scientific reports·2020
Same author

On the origin of extraordinary cyclic strengthening of the austenitic stainless steel Sanicro 25 during fatigue at 700°C.

Journal of materials research·2020
Same author

Beneficial effect of <i>Rhodopseudomonas palustris</i> on <i>in vitro</i> rumen digestion and fermentation.

Beneficial microbes·2020
Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013
Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013
Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013
Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013
Same journal

Schmallenberg virus.

Developments in biologicals·2013
Same journal

Classical swine fever.

Developments in biologicals·2013
See all related articles

Ensuring consistent biopharmaceutical production requires validated processes. While cell characterization is well-defined, biological process validation needs tailored approaches focusing on critical parameters for product quality.

Area of Science:

  • Biopharmaceutical Manufacturing
  • Process Validation
  • Cellular Biology

Background:

  • Consistent biopharmaceutical production relies on characterized cell substrates and validated processes.
  • International Council for Harmonisation (ICH) guidelines extensively detail cell characterization but offer limited specifics on biological process validation.
  • Current regulatory expectations for process validation in biologics are not universally defined.

Purpose of the Study:

  • To address the lack of specific guidance on process validation for biological manufacturing.
  • To explore the adaptability of validation concepts to diverse biological processes.
  • To propose a flexible approach to process validation in biopharmaceutical development.

Main Methods:

  • Review of existing guidelines on cell characterization and process validation.

Related Experiment Videos

  • Analysis of factors influencing the applicability of validation concepts to biological systems (process, product, knowledge level).
  • Conceptual framework development for tailoring validation rigor.

    • Main Results:

    • Validation applicability varies significantly based on process specifics, product attributes, and scientific understanding.
    • A one-size-fits-all approach to biological process validation is inappropriate.
    • Defining critical process parameters (CPPs) is a fundamental requirement for validation.

    Conclusions:

    • Biological process validation requires a risk-based and adaptable strategy, not a rigid, universal protocol.
    • Focusing validation efforts on identified critical process parameters is essential for ensuring product quality and consistency.
    • Further development of specific regulatory guidance for biological process validation is warranted.